Longitudinal body mass index and cancer risk: a cohort study of 2.6 million Catalan adults.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
30 06 2023
Historique:
received: 12 04 2022
accepted: 31 05 2023
medline: 3 7 2023
pubmed: 1 7 2023
entrez: 30 6 2023
Statut: epublish

Résumé

Single body mass index (BMI) measurements have been associated with increased risk of 13 cancers. Whether life course adiposity-related exposures are more relevant cancer risk factors than baseline BMI (ie, at start of follow-up for disease outcome) remains unclear. We conducted a cohort study from 2009 until 2018 with population-based electronic health records in Catalonia, Spain. We included 2,645,885 individuals aged ≥40 years and free of cancer in 2009. After 9 years of follow-up, 225,396 participants were diagnosed with cancer. This study shows that longer duration, greater degree, and younger age of onset of overweight and obesity during early adulthood are positively associated with risk of 18 cancers, including leukemia, non-Hodgkin lymphoma, and among never-smokers, head and neck, and bladder cancers which are not yet considered as obesity-related cancers in the literature. Our findings support public health strategies for cancer prevention focussing on preventing and reducing early overweight and obesity.

Identifiants

pubmed: 37391446
doi: 10.1038/s41467-023-39282-y
pii: 10.1038/s41467-023-39282-y
pmc: PMC10313757
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3816

Informations de copyright

© 2023. The Author(s).

Références

Endocrinol Diabetes Nutr. 2017 Mar;64 Suppl 1:15-22
pubmed: 27543006
Lancet. 2008 Feb 16;371(9612):569-78
pubmed: 18280327
BMJ Open. 2014 Sep 17;4(9):e005629
pubmed: 25231490
N Engl J Med. 2016 Aug 25;375(8):794-8
pubmed: 27557308
Am J Epidemiol. 1997 Jan 1;145(1):72-80
pubmed: 8982025
J Clin Epidemiol. 2006 Oct;59(10):1092-101
pubmed: 16980150
Int J Epidemiol. 2011 Aug;40(4):985-96
pubmed: 21357186
Cancer Med. 2022 Feb;11(4):1145-1159
pubmed: 35048536
Clin Epidemiol. 2019 Dec 03;11:1015-1024
pubmed: 31819655
Gut. 2020 Sep;69(9):1564-1571
pubmed: 32606208
J Clin Oncol. 2016 Sep 20;34(27):3237-9
pubmed: 27458311
Int J Cancer. 2008 Mar 15;122(6):1418-21
pubmed: 18027857
Br J Cancer. 2018 Apr;118(7):1013-1019
pubmed: 29527008
Annu Rev Med. 2010;61:301-16
pubmed: 19824817
BMC Med. 2021 Jan 14;19(1):10
pubmed: 33441148
Gac Sanit. 2008 May-Jun;22(3):179-87
pubmed: 18579042
Eur J Epidemiol. 2016 Sep;31(9):893-904
pubmed: 27300353
Int J Cancer. 2020 Mar 15;146(6):1541-1552
pubmed: 31187481
Lancet. 2014 Aug 30;384(9945):755-65
pubmed: 25129328
Epidemiology. 1999 Jan;10(1):37-48
pubmed: 9888278
Int J Epidemiol. 2022 Dec 13;51(6):e324-e336
pubmed: 35415748
Am J Clin Nutr. 2013 Oct;98(4):1057-65
pubmed: 23985810
Nat Rev Cancer. 2015 Aug;15(8):484-98
pubmed: 26205341
Br J Cancer. 2017 May 23;116(11):1486-1497
pubmed: 28441380
J Natl Cancer Inst. 2022 Mar 8;114(3):353-360
pubmed: 34743211
PLoS Med. 2016 Aug 16;13(8):e1002081
pubmed: 27529652
Nat Rev Cancer. 2004 Aug;4(8):579-91
pubmed: 15286738
Cancer Epidemiol Biomarkers Prev. 2021 Jan;30(1):104-113
pubmed: 33008875
Int J Cancer. 2020 Aug 1;147(3):793-802
pubmed: 31755107
Eur J Cancer. 2011 Nov;47(16):2422-30
pubmed: 21733676
Stat Med. 2009 Feb 1;28(3):389-411
pubmed: 18833567
Clin Epidemiol. 2017 Mar 15;9:157-166
pubmed: 28352203
Cancer Epidemiol Biomarkers Prev. 2009 Oct;18(10):2569-78
pubmed: 19755644
Nat Rev Cancer. 2011 Nov 24;11(12):886-95
pubmed: 22113164
Int J Cancer. 2008 May 1;122(9):2062-70
pubmed: 18167059

Auteurs

Martina Recalde (M)

International Agency for Research on Cancer (IARC-WHO), 25 avenue Tony Garnier, CS 90627, 69366 Lyon Cedex 07, Lyon, France.
Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.
Universitat Autònoma de Barcelona, Barcelona, Spain.

Andrea Pistillo (A)

Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.

Veronica Davila-Batista (V)

International Agency for Research on Cancer (IARC-WHO), 25 avenue Tony Garnier, CS 90627, 69366 Lyon Cedex 07, Lyon, France. vdavbat@gobiernodecanarias.org.
Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, 28029, Madrid, Spain. vdavbat@gobiernodecanarias.org.

Michael Leitzmann (M)

Department of Epidemiology and Preventive Medicine, University of Regensburg, Regensburg, Germany.

Isabelle Romieu (I)

Center for Research on Population Health, National Institute of Public Health, Mexico City, Mexico.

Vivian Viallon (V)

International Agency for Research on Cancer (IARC-WHO), 25 avenue Tony Garnier, CS 90627, 69366 Lyon Cedex 07, Lyon, France.

Heinz Freisling (H)

International Agency for Research on Cancer (IARC-WHO), 25 avenue Tony Garnier, CS 90627, 69366 Lyon Cedex 07, Lyon, France. FreislingH@iarc.fr.

Talita Duarte-Salles (T)

Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain. tduarte@idiapjgol.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH